Real-world evidence firms for IFX biosimilar

A string of real-world studies presented at this year’s ECCO congress point to the efficacy of infliximab biosimilar Inflectra in a range of IBD settings.

The ten studies from eight countries involve data from nearly 600 Crohn’s and ulcerative colitis patients who were switched from the reference drug Remicade to Inflectra.